Drugs / Fermented Deglycyrrhizinated Licorice
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07117942 | Feb 2020 → Jun 2021 | diabetic neuropathy | Helwan University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07148804 Comparator | Jan 2023 → Feb 2024 | diabetic polyneuropathy | Helwan University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fermented Deglycyrrhizinated Licorice | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07117942 ↗ |
| Known as | FDGL | “Fermented Deglycyrrhizinated Licorice (FDGL) in oral powder capsules; prepared through three consecutive steps: fermentation of licorice roots, removal of glycyrrhizinic acid...” NCT07117942 ↗1“α-amylase enzyme prepared from fermented deglycyrrhizinated licorice root extract (FDGL)” PMID 41627541 ↗ Feb 2026 |
| Route | Oral | “in oral powder capsules” NCT07117942 ↗ |